TIANDA PHARMA announced its 2024 performance, with a loss attributable to shareholders of HKD 61.371 million, an increase of 1.54 times year-on-year
I'm PortAI, I can summarize articles.
TIANDA PHARMA announced its 2024 performance, with revenue of approximately HKD 330 million, a year-on-year decrease of 37.99%; the loss attributable to shareholders was HKD 61.371 million, a year-on-year increase of 1.54 times, with a loss per share of HKD 0.0285. Revenue from the pharmaceuticals and medical technology business was HKD 283.9 million, down 39.7%. Revenue from traditional Chinese medicine business fell to HKD 27.1 million due to intense market competition. Revenue from medical and healthcare services increased to HKD 19 million
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments